National Center for Advancing Translational Sciences

The National Center for Advancing Translational Sciences (NCATS) was established in 2012[1] and is located in Bethesda, Maryland. NCATS is one of 27 institutes and centers of the US National Institutes of Health (NIH), an agency of the US Department of Health and Human Services. The mission of NCATS is to transform the translation of scientific discoveries so that new treatments and cures for disease can be delivered to patients faster. The budget provided to NCATS for fiscal year 2018 is $557,373,000.[2]

National Center for Advancing Translational Sciences (NCATS)
National Center for Advancing Translational Sciences logo.png
AbbreviationNCATS
Formation2011
TypeU.S. government agency
Legal statusActive
HeadquartersBethesda, Maryland, US
Director
Christopher P. Austin, M.D.
Parent organization
National Institutes of Health
AffiliationsUnited States Public Health Service
Websitencats.nih.gov
NCATS director Christopher P. Austin, M.D.

HistoryEdit

NCATS was created in December 2011 by the Consolidated Appropriations Act, 2012.[3]

The center was created from a number of existing NIH programs:[4]

DivisionsEdit

NCATS is organized into a number of divisions:

  • Office of Strategic Alliances: Works with businesses in the biotech and pharmaceutical industry to speed the development of new drugs[7]

Programs and initiativesEdit

OverviewEdit

The stated goal of NCATS is to promote research in both existing and new areas of medicine and science, in order to promote public health and to overcome high failure rates in clinical trials.[8][9] To accomplish this, NCATS supports 31 programs and initiatives that relate to translational research and improving the speed of therapeutic development.[10] The 31 programs and initiatives involve a range of STEM-related fields including biology, biochemistry, chemistry, bioengineering, virology, genetics, and data science.[11] Within the realm of translational science, issues that NCATS is particularly focused on addressing using its programs, initiatives, and partnerships include increasing the success and de-risking the costs associated with therapeutic development, incentivizing more collaborative work, and addressing data transparency issues.[12]

COVID responseEdit

During the COVID-19 pandemic, NCATS launched an open data initiative to promote collaborative sharing of COVID-related drug data.[13] An additional data sharing partnership with several other government institutes resulted in a study detailing the COVID-related risks for patients suffering from chronic obstructive pulmonary disease.[14][15]

See alsoEdit

ReferencesEdit

  1. ^ Wadman, Meredith (12 January 2012). "US translational-science centre gets under way". Nature. 481 (7380): 128. doi:10.1038/481128a. PMID 22237088.
  2. ^ "Budget". National Center for Advancing Translational Sciences. 12 March 2015.
  3. ^ "Archived copy". Archived from the original on 2014-03-16. Retrieved 2014-03-16.CS1 maint: archived copy as title (link)
  4. ^ Wadman, Meredith (12 January 2012). "US translational-science centre gets under way". Nature. 481 (7380): 128. doi:10.1038/481128a. PMID 22237088.
  5. ^ "NIH's Cures Acceleration Network (CAN) - Rare Disease Legislative Advocates". 12 May 2010.
  6. ^ "Cures Acceleration Network (CAN) Review Board - National Center for Advancing Translational Sciences". National Center for Advancing Translational Sciences.
  7. ^ a b "Divisions & Offices". National Center for Advancing Translational Sciences. 12 March 2015.
  8. ^ "About NCATS". National Center for Advancing Translational Sciences. 2017-10-30. Retrieved 2021-10-20.
  9. ^ Sacks, Leonard V.; Shamsuddin, Hala H.; Yasinskaya, Yuliya I.; Bouri, Khaled; Lanthier, Michael L.; Sherman, Rachel E. (2014-01-22). "Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012". JAMA. 311 (4): 378–384. doi:10.1001/jama.2013.282542. ISSN 0098-7484.
  10. ^ "NCATS Programs & Initiatives". National Center for Advancing Translational Sciences. 2015-03-16. Retrieved 2021-09-28.
  11. ^ "NCATS Programs & Initiatives". National Center for Advancing Translational Sciences. 2015-03-16. Retrieved 2021-10-20.
  12. ^ "Issues in Translation". National Center for Advancing Translational Sciences. 2015-03-12. Retrieved 2021-10-20.
  13. ^ "COVID-19 OpenData Portal". National Center for Advancing Translational Sciences. 2020-06-08. Retrieved 2021-10-01.
  14. ^ "N3C Data Reveals COVID-19's Stark Mortality Risk in People with COPD". National Center for Advancing Translational Sciences. 2021-09-23. Retrieved 2021-10-01.
  15. ^ Meza, Daniel; Khuder, Basil; Bailey, Joseph I; Rosenberg, Sharon R; Kalhan, Ravi; Reyfman, Paul A (August 2021). "Mortality from COVID-19 in Patients with COPD: A US Study in the N3C Data Enclave". International Journal of Chronic Obstructive Pulmonary Disease. Volume 16: 2323–2326. doi:10.2147/copd.s318000. ISSN 1178-2005. |volume= has extra text (help)